Denosumab in bone-metastatic prostate cancer: known effects on skeletal-related events but unknown effects on quality of life
- PMID: 21499282
- PMCID: PMC3739605
- DOI: 10.1038/aja.2011.33
Denosumab in bone-metastatic prostate cancer: known effects on skeletal-related events but unknown effects on quality of life
Comment on
-
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.Lancet. 2011 Mar 5;377(9768):813-22. doi: 10.1016/S0140-6736(10)62344-6. Epub 2011 Feb 25. Lancet. 2011. PMID: 21353695 Free PMC article. Clinical Trial.
References
-
- Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, et al. Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458–68. - PubMed
-
- http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Informat... (accessed 20 March 2011).
Publication types
LinkOut - more resources
Full Text Sources